-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Down syndrome (DS) is the most common cause of inherited intellectual disability (ID), affecting 8 million people worldwi.
Among DS patients, Alzheimer's disease (AD) is the leading cause of dea.
Therefore, DS is considered to be an inherited form of dementia, similar to autosomal dominant AD (ADA.
Importantly, clinical and AD biomarker changes were strikingly similar between the two populatio.
The purpose of this study was to explore the clinical progression of AD and its associated cognitive decline in DS patients, and to explore the existence of practice and bottom effects through repeated assessmen.
Among DS patients, Alzheimer's disease (AD) is the leading cause of dea.
Therefore, DS is considered to be an inherited form of dementia, similar to autosomal dominant AD (ADA.
Importantly, clinical and AD biomarker changes were strikingly similar between the two populatio.
The purpose of this study was to explore the clinical progression of AD and its associated cognitive decline in DS patients, and to explore the existence of practice and bottom effects through repeated assessmen.
Down syndrome (DS) is the most common cause of inherited intellectual disability (ID), affecting 8 million people worldwi.
Among DS patients, Alzheimer's disease (AD) is the leading cause of dea.
The purpose of this study was to explore the clinical progression of AD and its associated cognitive decline in DS patients, and to explore the existence of practice and bottom effects through repeated assessmen.
This is a single-centre cohort study of adults (age >18 years) with DS at different levels of ID and followed up for at least 6 months between November 2012 and December 202 Data were obtained from a population-based health program aimed at screening for AD in adults with DS in Catalonia, Spa.
Individuals were classified as asymptomatic, prodromal AD or AD dement.
The primary outcome was clinical changes across the AD continu.
Cognitive decline was measured by the Cambridge Cognitive Examination and Modified Cue Recall Test in Older Adults with Down Syndro.
Individuals were classified as asymptomatic, prodromal AD or AD dement.
The primary outcome was clinical changes across the AD continu.
Cognitive decline was measured by the Cambridge Cognitive Examination and Modified Cue Recall Test in Older Adults with Down Syndro.
The primary outcome of the screening was clinical change across the AD continu.
Cognitive decline was measured by the Cambridge Cognitive Examination and Modified Cue Recall Test in Older Adults with Down Syndro.
At the end of the study, a total of 632 adults with DS (mean [SD] age, 46 [14] years; 292 women [42%]) were assessed for 2847 assessments (mean [SD] follow-up 28 [17] month.
At baseline, there were 436 asymptomatic individuals, 69 with prodromal AD, and 127 with AD dement.
At baseline, there were 436 asymptomatic individuals, 69 with prodromal AD, and 127 with AD dement.
Clinical progression of asymptomatic and prodromal Alzheimer's disease (AD) in adults with Down syndrome (DS)
Clinical progression of asymptomatic and prodromal Alzheimer's disease (AD) in adults with Down syndrome (DS)After 5 years of follow-up, 11% (95% CI, 15%-25%) of asymptomatic individuals developed symptomatic AD in an age-dependent manner, and 91% (75% CI, 86%-90%) of prodromal AD patients Development of non-age dependent dement.
Cognitive decline in older adults is most common in those who progress to symptomatic AD and those with sympto.
Importantly, individuals with mild and moderate ID did not differ in longitudinal cognitive decline, although at baseline they differ.
The study also found practice and floor effects, which masked the assessment of longitudinal cognitive decli.
Cognitive decline in older adults is most common in those who progress to symptomatic AD and those with sympto.
Importantly, individuals with mild and moderate ID did not differ in longitudinal cognitive decline, although at baseline they differ.
The study also found practice and floor effects, which masked the assessment of longitudinal cognitive decli.
After 5 years of follow-up, 11% (95% CI, 15%-25%) of asymptomatic individuals developed symptomatic AD in an age-dependent manner, and 91% (75% CI, 86%-90%) of prodromal AD patients Development of non-age dependent dement.
Cognitive decline in older adults is most common in those who progress to symptomatic AD and those with sympto.
Individuals with mild and moderate ID did not differ in longitudinal cognitive decline, although they differed at baseli.
In conclusion, this study finds a high-risk association between the development of symptomatic AD and progressive cognitive decline in DS patients, and informs clinical trials for AD prevention
in adults with D.
in adults with D.
This study found a high-risk association between the development of symptomatic AD and progressive cognitive decline in patients with DS, informing clinical trials for AD prevention
in adults with D.
prevention
Reference: Videla L, Benejam B, Pegueroles J, et .
Reference: Videla L, Benejam B, Pegueroles J, et .
Longitudinal Clinical and Cognitive Changes Along the Alzheimer Disease Continuum in Down Syndro.
JAMA Netw Op.
2022;5(8):e222557 doi:11001/jamanetworkop.
20225573 JAMA Netw Op.
JAMA commented here
